Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carly Reeder"'
Autor:
Cornelius H. L. Kürten, Aditi Kulkarni, Anthony R. Cillo, Patricia M. Santos, Anna K. Roble, Sayali Onkar, Carly Reeder, Stephan Lang, Xueer Chen, Umamaheswar Duvvuri, Seungwon Kim, Angen Liu, Tracy Tabib, Robert Lafyatis, Jian Feng, Shou-Jiang Gao, Tullia C. Bruno, Dario A. A. Vignali, Xinghua Lu, Riyue Bao, Lazar Vujanovic, Robert L. Ferris
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
The tumor microenvironment (TME) has an important role in Head and Neck Squamous Cell Carcinoma (HNSCC) progression. Here, using single-cell RNA sequencing and multiplexed imaging, the authors report the cellular complexity of the TME in patients wit
Externí odkaz:
https://doaj.org/article/2771653d57ef4d11b987a7dbc52724d2
Autor:
Robert L. Ferris, Soldano Ferrone, Carly Reeder, Sandra P. Gibson, Fernando Concha-Benavente, Sumita Trivedi, Raghvendra M. Srivastava
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is impor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb6f59898a7882ea3f4f48072767d7e
https://doi.org/10.1158/1078-0432.c.6525459
https://doi.org/10.1158/1078-0432.c.6525459
Autor:
Robert L. Ferris, Soldano Ferrone, Carly Reeder, Sandra P. Gibson, Fernando Concha-Benavente, Sumita Trivedi, Raghvendra M. Srivastava
Supplementary Figure S1: Gating strategy to dendritic cells (upper panel), CD56+ NK cells ( lower panel) in the coculture experiment; Supplementary Figure S2A: NK cell viability after Urelumab treatment; Supplementary Figure S2B: Evaluation of CD137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1951840c1a42d400aec656a76154624e
https://doi.org/10.1158/1078-0432.22463613.v1
https://doi.org/10.1158/1078-0432.22463613.v1
Autor:
Soldano Ferrone, Raghvendra M. Srivastava, Carly Reeder, Fernando Concha-Benavente, Robert L. Ferris, Sandra P. Gibson, Sumita Trivedi
Publikováno v:
Clinical Cancer Research. 23:707-716
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer (HNC). Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is impor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cf362ba6673c78e3162a33abcf64981
https://doi.org/10.1158/1078-0432.ccr-16-0879
https://doi.org/10.1158/1078-0432.ccr-16-0879